test group-1600mg:Oral 1600mg product
Sponsors
Peking University First Hospital
Conditions
Primary hyperlipidemia
Phase 2
Preliminary evaluation of the efficacy and safety of Xuezhikang tablets (LY02404) in the treatment of hyperlipidemia: a multicenter, randomized, double-blind, double-simulation, parallel control of positive drugs, and dose-exploration phase II clinical trial
Active, not recruitingITMCTR2000003402
Start: 2020-07-01Updated: 2023-02-20
Preliminary evaluation of the efficacy and safety of Xuezhikang tablets (LY02404) in the treatment of hyperlipidemia: a multicenter, randomized, double-blind, double-simulation, parallel control of positive drugs, and dose-exploration phase II clinical trial
Active, not recruitingChiCTR2000033914
Start: 2020-07-01Updated: 2020-06-22